Skip to main
MDAI

MDAI Stock Forecast & Price Target

MDAI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spectral AI is already seeing success as it has secured a $18.5M revenue contract with the BARDA, and the company has plans to expand its market opportunities through regulatory and clinical milestones. Additionally, the recent FDA clearance for the DeepView System further solidifies MDAI's potential for rapid growth and recurring high-margin revenue. With a potential 110% CAGR in revenue through FY26-30 and its innovative technology poised to disrupt the large and under-penetrated Advanced Wound Care market, Spectral AI is well-positioned for success in the MedTech industry.

Bears say

Spectral AI is facing potential downside to its estimates due to slow clinical and regulatory development timelines resulting in lower revenue from the BARDA PBS contract. Additionally, there is a risk of setbacks in regulatory and commercial approvals, which could require further analysis, filings, or additional clinical data. Furthermore, if there is lower uptake of the DeepView system in a commercial setting, it could also impact the company's revenue. On the upside, faster clinical and regulatory developments could lead to higher BARDA-related revenue, as well as more rapid development and commercial approval for the DeepView and DeepView M systems. Expansion into new indications and opportunities could also increase revenue, as could securing non-dilutive financing sources for international commercial opportunities or government contracts. If commercial sales are achieved in the UK or Australia, it would also be a positive for the company's revenue. However, this outlook remains negative overall due to the potential for longer timelines and lower uptake, which could impact Spectral AI's financials.

MDAI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spectral AI Inc (MDAI) Forecast

Analysts have given MDAI a Strong Buy based on their latest research and market trends.

According to 1 analysts, MDAI has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spectral AI Inc (MDAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.